Amphinex

Amphinex is a photosensitizing agent used in photodynamic therapy (PDT) for the treatment of various cancers. It is a proprietary formulation developed by the Norwegian company PCI Biotech. Amphinex is designed to enhance the delivery and efficacy of chemotherapeutic agents by utilizing light activation to target cancer cells more precisely.

Mechanism of Action

Amphinex works by binding to cancer cells and, upon activation by a specific wavelength of light, produces reactive oxygen species (ROS). These ROS cause damage to the cellular components, leading to cell death. The light activation allows for localized treatment, minimizing damage to surrounding healthy tissues.

Applications

Amphinex is primarily used in the treatment of head and neck cancers, but research is ongoing to explore its efficacy in other types of cancer, including pancreatic cancer and bladder cancer. The agent is often used in combination with other chemotherapeutic drugs to enhance their delivery and effectiveness.

Clinical Trials

Several clinical trials have been conducted to evaluate the safety and efficacy of Amphinex. These trials have shown promising results, with significant tumor reduction observed in patients treated with Amphinex in combination with other therapies.

Advantages

• Targeted treatment: Amphinex allows for precise targeting of cancer cells, reducing damage to healthy tissues.
• Enhanced drug delivery: The photosensitizing properties of Amphinex improve the uptake and efficacy of chemotherapeutic agents.
• Minimally invasive: PDT with Amphinex is less invasive compared to traditional surgical methods.

Related Pages

• Photodynamic therapy
• PCI Biotech
• Cancer treatment
• Chemotherapy
• Reactive oxygen species

See Also

• Head and neck cancer
• Pancreatic cancer
• Bladder cancer